EUVIMEDEUVIMED entdecken
Crossref

Removal of UK‐donor deferral for variant Creutzfeldt–Jakob disease: A large donation gain in Australia

Veronica C Hoad iD, Clive R Seed iD, Philip Kiely iD, Claire E Styles iD, Hamish McManus iD, Matthew Law, John Kaldor, Iain B Gosbell

Vox Sanguinis · 2023

DOI: 10.1111/vox.13510 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vox Sanguinis, 2023. Verfasst von Veronica C Hoad und 7 weiteren Autor:innen. Beteiligte Einrichtung: Australian Red Cross Lifeblood, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Creutzfeldt-Jakob Syndrome. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 7 Literaturangaben. Gefördert von: National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives Until 25 July 2022, people who spent more than 6 months in the United Kingdom during the variant Creutzfeldt–Jakob disease (vCJD) risk period 1980–1996 (UK donors) were deferred from blood donation in Australia. Regulatory approval to remove the deferral was underpinned by published mathematical modelling predicting negligible vCJD transmission risk increase with a gain of 58,000 donations. Materials and Methods The donor questionnaire retained the UK deferral screening question until a version update effective 12 February 2023, which enabled identification of the newly eligible cohort of UK donors. Their donations were tracked for a 6‐month period (25 July 2022–24 January 2023) and compared with baseline Lifeblood donation metrics and predicted gains.

Results

A total of 38,462 UK donors attended to donate 78,762 times in the 6 months. Of these, 32,358 donors (females = 19,456, males = 12,902) successfully donated 67,914 times representing 8.4% of total collections.

Conclusion

Cessation of the UK deferral resulted in donation gains exceeding modelled predictions because of a higher than predicted number of donors who donated at a higher rate. Had these newly eligible donors not donated, overall donation numbers would have been 88% of target rather than the 96% achieved.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Creutzfeldt-Jakob SyndromeMaleFemaleHumansBlood DonorsBlood DonationAustraliaUnited Kingdom

Stichwörter der Autor:innen

blood donationblood safetydonor eligibilitytransfusion transmitted infectionsvCJD

Autor:innen und Institutionen

  • Australian Red Cross Lifeblood, Melbourne, Victoria, Australia.
  • Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
  • School of Medicine, Western Sydney University, Penrith, New South Wales, Australia.

ORCID-Profile: Veronica C Hoad, Clive R Seed, Philip Kiely, Claire E Styles, Hamish McManus

Förderung

  • National Health and Medical Research Council

Zitieren

APA

Hoad, V. C., Seed, C. R., Kiely, P., Styles, C. E., McManus, H., Law, M., Kaldor, J., & Gosbell, I. B. (2023). Removal of UK‐donor deferral for variant Creutzfeldt–Jakob disease: A large donation gain in Australia. Vox Sanguinis. https://doi.org/10.1111/vox.13510

Vancouver

Hoad VC, Seed CR, Kiely P, Styles CE, McManus H, Law M, et al. Removal of UK‐donor deferral for variant Creutzfeldt–Jakob disease: A large donation gain in Australia. Vox Sanguinis. 2023. doi:10.1111/vox.13510

BibTeX
@article{Hoad2023,
  author = {Hoad, Veronica C and Seed, Clive R and Kiely, Philip and Styles, Claire E and McManus, Hamish and Law, Matthew and Kaldor, John and Gosbell, Iain B},
  title = {Removal of UK‐donor deferral for variant Creutzfeldt–Jakob disease: A large donation gain in Australia},
  journal = {Vox Sanguinis},
  year = {2023},
  doi = {10.1111/vox.13510}
}
Kostenlos starten →